Loading…
Loading…
TITMF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for TITMF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TITMF and 80,000+ other tickers.
See exactly how TITMF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TITMF and 80,000+ other tickers.
Titomic Ltd. engages in the manufacture and provision of technology solutions for metal additive manufacturing, metal coatings, and repairs using Titomic Kinetic Fusion cold spray technology. It operates through the following segments: Australia, USA, and Netherlands. The Australia segment includes high pressure cold spray additive manufacturing machines and manufactures products for customers in the Aerospace and Defense industry segments. The USA segment focuses on the sales, marketing, and customer relationship activities in the U.S. The Netherlands segment relates to low and medium…
Rocket Pharmaceuticals (NASDAQ:RCKT) announced that the US Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI (marnetegragene...
Titomic Ltd (ASX:TTT, OTC:TITMF, FRA:T04) has secured a EUR1.02 million (about A$1.71 million) purchase order from Royal NLR, the Netherlands’ national...
Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', arguing that a recent pullback in the stock has created a more...
UBS analysts maintained a ‘Buy’ rating on Microsoft Corp (NASDAQ:MSFT), while lowering their 12-month price target to $510 from $600, citing investor...
Atlassian (NASDAQ:TEAM) has announced plans to cut roughly 10% of its workforce, or about 1,600 jobs, as part of a restructuring aimed at increasing...